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Abstract 
Imatinib mesylate, as treatment for gastrointestinal stromal tumors (GIST), has 
dramatically changed the prognosis for survival – not only because it is efficacious, but 
also because it attracted attention to this malignant disease. GIST is now a well-known 
disease entity and a paradigm for targeted therapies in malignant diseases. A now 74-
year-old patient presented with recurrence of a primary duodenal GIST (initial diagnosis 
and primary resection in 1998; diameter 10 cm, KIT exon 11 mutation, PM V559D) and 
liver metastasis after a second surgical resection was performed in 2000. Conventional 
chemotherapy with adriamycin and ifosfamide failed to control growth of the relapsed 
tumor and liver metastasis. In July 2001, compassionate use of imatinib was started. 
Tumor regression was observed at continuous follow-ups (every 2 months for the first 6 
months, and 6 months thereafter) and persisted until now. The patient’s physical 
performance has remained in good condition. Side effects consisted of periorbital edema 
and sudden muscle cramps of toes and fingers, pain of bones and joints, an intentional 
tremor, a paler color of the skin, as well as a slight anemia. Imatinib is the first orally 
administered anticancer drug. Our case shows that a sustained response is possible with 
continuous therapy over a long time, if the drug is well tolerated. This implies a high 
compliance of the patient and suggests that resistance to imatinib does not have to 
develop. Exon 11 (point) mutation might not only represent a positive predictor for 
imatinib response in general, but especially for imatinib response on long-term. 
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Introduction 
The gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor 
of the gastrointestinal tract. It is a rare (10–20 cases per 1,000,000/year) malignant tumor. 
GIST develops most frequently in the muscular layer of the gastric wall (60–70% of the 
cases) and less frequently in the small (~30%) and large intestine (5%) [1]. The tumor 
remains asymptomatic for a long time until abdominal pain caused by obstruction of the 
small intestine, or bleeding occurs due to luminal-ulceration of tumors located in the 
stomach. It is not uncommon for the tumor to have already metastasized intraperitoneally 
or into the liver at the time of diagnosis. The therapy consists of surgical resection 
whenever possible. It has been established that the risk of recurrence may be estimated 
according to location and size of the tumor as well as the number of mitoses counted in 
50 high power fields (HPF) [1]. Tumors with a ‘significant’ risk of recurrence (after R0 
resection) are treated with imatinib as an adjuvant therapy for at least 1 year [2], but 
patients with high risk of recurrence need such treatment for a longer period [3, 4]. 
Prior to introduction of imatinib, patients with non-operable advanced or metastatic 
GIST had a median survival of 14–18 months [5]. Introduction of imatinib has increased 
the median overall survival in patients with advanced GIST to 57 months [6]. Patients 
with inoperable advanced tumors or with non-resectable recurrent tumors are now 
treated with imatinib (400 mg) as the first-line therapy with a clinical benefit rate of up to 
84% [5]. This treatment is continued until drug intolerance or initial resistance (2–3 
months after starting the therapy) becomes apparent or late resistance occurs. 
Follow-up strategies have been suggested [7] but as experience accumulates, they may 
need to be reconsidered as patients treated with 400 mg imatinib daily can still do well 
after 9 years of therapy [8]. 
Case Report 
A 62-year-old man was diagnosed with a necrotic tumor perforating to the descending part of the 
duodenum. This was determined by endoscopy and by a computed tomography (CT) scan of the 
abdomen in June 1998 (fig. 1, upper panel). Histopathological examination lead to the diagnosis of a c-
kit-positive mesenchymal tumor (fig. 1, lower panel) with a maximal diameter of 10 cm and a 
proliferation activity of 30 mitoses/50 HPF. Genetic analysis detected an exon 11 mutation (point 
mutation V559D). 
After diagnosis, surgical resection of the primary tumor was performed. However, local relapse and 
liver metastasis were apparent 18 months thereafter. In February 2000, atypical partial liver resection 
and tumor reduction of the retroperitoneal tumor mass were performed. Conventional chemotherapy 
treatment with adriamycin and ifosfamide was started in March 2000 (4 cycles). Although some efficacy 
of the treatment was detectable by density changes of the tumor within the CT scan (fig. 2), the primary 
tumor and metastasis continuously increased in size (fig. 3). In July 2001, 2 months after imatinib was 
approved by the FDA for the treatment of chronic myeloid leukemia in May 2001 [9], and 3 months 
after the first successful treatment of a patient with metastatic GIST [10], treatment with imatinib 400 
mg was started in our patient. Imatinib therapy was started as compassionate use, with the patient 
having given written informed consent outside of a clinical trial. Continuous reduction of the tumor 
mass and tumor density was shown by repeated imaging: 3 magnetic resonance tomographies (MRT) 
and 1 CT scan were performed during the first 6 months of the treatment and every 6 months 
thereafter. Up to now, 27 CT and 4 MRT scans of the abdomen have been performed. The treatment 
was well tolerated and has been continued to date. Long-term side effects have included periorbital 
edema and sudden muscle cramps of the toes and fingers, pain of bones and joints as well as an 
intentional tremor and a paler skin color, which has to be distinguished from the slight anemia. In Case Rep Oncol 2011;4:505–511 
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general, the patient is doing well with a Karnofsky index of 90%. Follow-up checks have been extended, 
now consisting of alternating CT scan and ultrasonography of the abdomen at 6-month intervals. 
Discussion 
Imatinib is the first orally administered anticancer drug able to induce a long-lasting 
response in a solid malignant tumor. We here present the first case of treatment with 
imatinib, 400 mg daily, for recurrence of a duodenal GIST, which has now been 
administered daily for more than 10 years without treatment interruption. This implies a 
high compliance of the patient, and is in agreement with other observations suggesting 
that resistance to therapy rarely occurs if it does not develop within the first 2 years of 
treatment [8, 11]. As has been reported in the literature [8], GIST patients can be treated 
for more than 6 years with imatinib safely, without major side effects, if they tolerate 
imatinib during the first months of the treatment. Once they develop disease progression 
under imatinib therapy, about 30% of the patients die within 31 months [11]. Exon 11 
mutation might not only represent a positive predictor for imatinib response in general, 
but especially for the long-term imatinib response [6]. In fact, the vast majority of the 
long-term survivors in the French BFR14 trial [12], as well as the American B2222 trial [8] 
had exon 11 mutations. A point mutation, such as in our patient, seems to be more 
favorable than deletions affecting codons 557 to 558 of the KIT gene [13]. 
Furthermore, the French group’s experience shows that therapy interruption in 
initially advanced GIST leads to tumor recurrence. Although re-introduction of the 
therapy is successful in most of the cases [14], some will not respond to the therapy and 
will possibly die of the disease. This suggests that imatinib therapy, if successful and well 
tolerated, should be continued in metastasized GIST, even in patients considered having a 
complete response. Post-imatinib surgery in responders with residual tumors has been 
discussed but randomized trials are needed before recommendations can be given [15]. 
Follow-up CT scans for high-risk GIST have been suggested at intervals of 3–4 months 
for 3 years and every 6 months until 5 years, and yearly afterwards [7]. In cases of 
sustained response under treatment, such as our case, a reduction of the number of 
tomographies after 3–5 years might be suggested. As tumor recurrence tends to be intra-
abdominal, recurrence can also be detected by a specialist performing sonography, 
although CT scan of the abdomen is still the standard in the follow-up of GIST. 
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Fig. 1. Upper panel: CT scan of the abdomen showing a cystic abdominal mass. The necrotic tumor of 
the duodenum is filled with contrast medium, the perforation to the duodenum is indicated with an 
arrow. Lower panel: Representative paraffin sections of the duodenal GIST (original magnification 
200×). The sections show a spindle cell (HE staining), ckit-positive (CD117), smooth muscle actin 
(SMA)-positive and desmin-negative mesenchymal tumor. 
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Fig. 2. CT scans of the abdomen at diagnosis of local recurrence (marked with an ellipse) and liver 
metastasis (upper panel), and after chemotherapy with adriamycin and ifosfamide was started in March 
2000 (middle and lower panel). The left-hand side shows the retroperitoneal tumor mass, the right-hand 
side depicts the liver metastasis. 
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Fig. 3. CT scan of the abdomen showing the retroperitoneal and liver tumor burden before starting 
imatinib therapy (07/2001) and the residual liver metastasis under continuous therapy with imatinib, 
performed at different time points (as indicated). 
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